JP2021519786A - チエノピリミジノン化合物 - Google Patents

チエノピリミジノン化合物 Download PDF

Info

Publication number
JP2021519786A
JP2021519786A JP2020552869A JP2020552869A JP2021519786A JP 2021519786 A JP2021519786 A JP 2021519786A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2021519786 A JP2021519786 A JP 2021519786A
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020552869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519786A5 (cg-RX-API-DMAC7.html
Inventor
チャン, カイル ダブリュー.エイチ.
チャン, カイル ダブリュー.エイチ.
アパラジタ ホスコテ チョウラシア,
アパラジタ ホスコテ チョウラシア,
ポール イー. エルドマン,
ポール イー. エルドマン,
リア ファン,
リア ファン,
イメルダ ラム,
イメルダ ラム,
フランク メルキューリオ,
フランク メルキューリオ,
ロバート サリバン,
ロバート サリバン,
エドゥアルド トーレス,
エドゥアルド トーレス,
Original Assignee
バイオセリックス, インコーポレイテッド
バイオセリックス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオセリックス, インコーポレイテッド, バイオセリックス, インコーポレイテッド filed Critical バイオセリックス, インコーポレイテッド
Publication of JP2021519786A publication Critical patent/JP2021519786A/ja
Publication of JP2021519786A5 publication Critical patent/JP2021519786A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020552869A 2018-03-30 2019-03-28 チエノピリミジノン化合物 Pending JP2021519786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650922P 2018-03-30 2018-03-30
US62/650,922 2018-03-30
PCT/US2019/024612 WO2019191451A1 (en) 2018-03-30 2019-03-28 Thienopyrimidinone compounds

Publications (2)

Publication Number Publication Date
JP2021519786A true JP2021519786A (ja) 2021-08-12
JP2021519786A5 JP2021519786A5 (cg-RX-API-DMAC7.html) 2022-04-04

Family

ID=66102328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020552869A Pending JP2021519786A (ja) 2018-03-30 2019-03-28 チエノピリミジノン化合物

Country Status (8)

Country Link
US (1) US10584133B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774815A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021519786A (cg-RX-API-DMAC7.html)
CN (1) CN112313236A (cg-RX-API-DMAC7.html)
AU (1) AU2019243186A1 (cg-RX-API-DMAC7.html)
CA (1) CA3094988A1 (cg-RX-API-DMAC7.html)
TW (1) TW202003524A (cg-RX-API-DMAC7.html)
WO (1) WO2019191451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105335A1 (en) * 2019-11-27 2021-06-03 Captor Therapeutics S.A. Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
MX2022012677A (es) * 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
WO2022255890A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof
WO2023001028A1 (zh) * 2021-07-19 2023-01-26 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
US12662467B2 (en) 2022-04-18 2026-06-23 BioThery X, Inc. Isoindolinones, pharmaceutical compositions, and therapeutic applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516821A (ja) * 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ,エルエルシー 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334596A (en) 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CA2476583C (en) 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
WO2005047293A1 (en) 2003-11-07 2005-05-26 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
TWI642670B (zh) 2010-09-14 2018-12-01 伊塞利克斯公司 Pi3k-德爾塔抑制劑以及其應用和生產方法
SI2683384T1 (sl) * 2011-03-11 2016-05-31 Celgene Corporation Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 mGluR1 길항제로 작용하는 사이에노피리미디논 유도체
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
EP3399980B1 (en) * 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
JP2020504711A (ja) * 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516821A (ja) * 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ,エルエルシー 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法
WO2017161119A1 (en) * 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. 535, JPN6023008352, 2016, pages 252 - 257, ISSN: 0005003423 *

Also Published As

Publication number Publication date
US20190322682A1 (en) 2019-10-24
WO2019191451A1 (en) 2019-10-03
CN112313236A (zh) 2021-02-02
CA3094988A1 (en) 2019-10-03
AU2019243186A1 (en) 2020-10-15
EP3774815A1 (en) 2021-02-17
TW202003524A (zh) 2020-01-16
US10584133B2 (en) 2020-03-10

Similar Documents

Publication Publication Date Title
US11345714B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US11400084B2 (en) Aminoamide compounds
US10584133B2 (en) Thienopyrimidinone compounds
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
US11285218B2 (en) Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
JP6629885B2 (ja) タンパク質を標的とする化合物、その組成物、方法、および使用
JP2022510313A (ja) Heliosの低分子分解誘導剤および使用方法
CN113498342A (zh) 参与协同结合的化合物和其用途
JP2021527098A (ja) 縮合チオフェン化合物
JP2022507267A (ja) 置換イソインドリノン
TW202019936A (zh) 雙功能化合物
CN105073750A (zh) 布鲁顿氏酪氨酸激酶抑制剂
US10723705B2 (en) Heterocyclic compounds and uses thereof
JP2022522890A (ja) 芳香族誘導体、その調製方法および医薬用途
US20250092043A1 (en) Kinase Inhibitors and Degraders
US10550125B2 (en) Prodrugs of imidazotriazine compounds as CK2 inhibitors
HK40005135A (en) Pyrazole derivatives, compositions and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231002